Healthcare AI Companies in 2026

Healthcare AI Companies to know

Companies were chosen for notability as of October 2026. The measures were publicly reported funding and valuation, public-market listing, clinical adoption (health-system deployments and physician usage) and press coverage. Each company had to be active and build clinical or care-delivery products: documentation, decision support, diagnostics or imaging, patient-facing agents, or drug discovery. Healthcare data and commercial-intelligence vendors were left out because they belong in the Healthcare Intelligence directory. The list spans several sub-segments (ambient documentation, clinician evidence search, imaging AI, patient-facing agents, precision diagnostics and AI drug discovery) so that no single niche dominates.

1. 

   OpenEvidence

   AI medical evidence search and clinical reference platform for clinicians

   OpenEvidence builds an AI search engine over peer-reviewed medical literature that verified U.S. clinicians use for point-of-care questions. Besides the core search product, it offers DeepConsult for multi-study clinical reasoning, plus Visits for documentation and Voice Mode. It is free for verified physicians and funded by advertising, and it reported about 760,000 registered U.S. physicians as of December 2025.

   Headquarters

   Miami, Florida, USA

   Website ↗
2. 

   Abridge

   Ambient AI clinical documentation integrated into health-system EHR workflows

   Abridge makes ambient AI software that turns patient-clinician conversations into structured clinical notes and links each note to timestamps in the source audio. It sells to large health systems, offering products for outpatient, inpatient, nursing and revenue-cycle documentation, and integrates with Epic. Disclosed customers include Kaiser Permanente, Mayo Clinic, Johns Hopkins and Duke Health.

   Headquarters

   San Francisco, California, USA

   Website ↗
3. 

   Tempus AI

   Publicly listed precision-medicine company combining genomic testing with AI

   Tempus AI provides genomic sequencing and diagnostic tests together with AI-enabled analytics, mainly in oncology and also in cardiology, radiology and depression. It combines clinical and molecular data with AI tools that support physicians' treatment decisions and pharmaceutical research. The company is listed on Nasdaq.

   Headquarters

   Chicago, Illinois, USA

   Website ↗
4. 

   Isomorphic Labs

   Alphabet-backed AI drug design company spun out of Google DeepMind

   Isomorphic Labs builds AI models for drug design and runs its own internal therapeutic pipeline, focused mainly on oncology and immunology. It was spun out of DeepMind, co-developed AlphaFold 3 and announced its IsoDDE drug design engine in 2026. The company reported that it expected to begin its first clinical trials by the end of 2026.

   Headquarters

   London, UK

   Website ↗
5. 

   Hippocratic AI

   Patient-facing generative AI agents for non-diagnostic clinical tasks

   Hippocratic AI builds patient-facing generative AI agents for non-diagnostic clinical tasks such as pre-operative calls, discharge follow-up, chronic care management and trial enrollment. The agents run on the company's Polaris safety architecture. As of November 2025, the company reported partnerships with more than 50 health systems, payers and pharmaceutical clients in six countries.

   Headquarters

   Palo Alto, California, USA

   Website ↗
6. 

   Ambience Healthcare

   Ambient AI documentation and coding platform for health systems

   Ambience Healthcare builds an ambient AI platform that drafts clinical documentation from patient encounters and suggests codes (HCC, E/M, ICD-10 and CPT) in real time. It supports more than 100 specialties and has been deployed at health systems including Cleveland Clinic, UCSF Health and Houston Methodist.

   Headquarters

   San Francisco, California, USA

   Website ↗
7. 

   Insilico Medicine

   Hong Kong-listed AI drug discovery company with a clinical-stage pipeline

   Insilico Medicine uses generative AI and deep learning to identify drug targets and design molecules, both for its own pipeline and for partners through its Pharma.AI software. Its lead candidate, rentosertib (INS018_055), was in a phase 3 trial as of 2026. In March 2026 it signed an AI drug discovery agreement with Eli Lilly worth up to $2.75B, including $115M upfront.

   Headquarters

   Cambridge, Massachusetts, USA

   Website ↗
8. 

   Aidoc

   Always-on AI for triaging acute findings in medical imaging

   Aidoc builds AI that runs in the background on medical imaging studies and flags acute findings, such as intracranial hemorrhage, pulmonary embolism, cervical spine fractures and large-vessel occlusion strokes, for faster triage. Its algorithms are deployed in more than 900 hospitals and imaging centers, including Yale New Haven Hospital and Cedars-Sinai.

   Headquarters

   Tel Aviv, Israel

   Website ↗
9. 

   Xaira Therapeutics

   AI drug discovery and development company with an integrated lab platform

   Xaira Therapeutics builds AI models for target identification, molecule design and patient identification, and combines them with agentic AI and lab robotics to develop its own therapeutics. Its platform includes the X-Cell, X-Design and X-Patient models. The company launched publicly in April 2024 with about $1B in capital and in 2026 revealed an antibody platform and its first pipeline candidates.

   Headquarters

   South San Francisco, California, USA

   Website ↗
10. 

    Recursion

    Clinical-stage biotech running an AI and automated-lab drug discovery platform

    Recursion runs Recursion OS, a drug discovery platform that combines large-scale automated biology experiments, generative chemistry and translational tools. The company says it runs up to 2 million experiments a week and holds a proprietary dataset of more than 50 petabytes. Its clinical pipeline covers oncology and rare diseases, and it has partnerships with Roche, Sanofi and Bayer.

    Headquarters

    Salt Lake City, Utah, USA

    Website ↗